For this study, researchers identified randomized controlled trials that included adults with moderate-to-severe CD treated with various biologic agents (i.e., infliximab, adalimumab, certolizumab pegol, vedolizumab, ustekinumab) as first- or second-line therapies compared with placebo or an active comparator.
There is a lack of evidence for efficacy of pharmacologic agents and emerging evidence of significant harm; consequently, these agents should be used sparingly, if at all.
The first patient has been enrolled in PEDFIC-1, a phase 3, single, randomized, double-blind, placebo-controlled trial designed to evaluate A4250 in 60 patients (aged 6 months-18 years) with PFIC subtype 1 or 2 who have elevated serum bile acid (sBA) levels and pruritus.
The researchers found that 31% of the patients assigned to bezafibrate had a complete biochemical response (normal levels of total bilirubin, alkaline phosphatase, aminotransferases, and albumin as well as a normal prothrombin index) vs none assigned to placebo.
Noting that infants and children who ingest button batteries can experience esophageal damage leading to significant morbidity and death in as little as 2 hours, researchers from the Children's Hospital of Philadelphia and Nationwide Children's Hospital aimed to identify effective options for mitigating these effects by testing common weakly acidic household beverages, viscous liquids, and sucralfate (Carafate).
The researchers found that the mean DeMeester score was 44 ± 33 for GERD+ and 7 ± 4 for GERD−. For GERD+ and GERD−, the mean HADS scores for anxiety (8 for both; P=0.2) and depression (5 and 6, respectively; P=.3) did not differ significantly.
The new analysis pooled patients from the UNITI-1 and UNITI-2 trials who had clinical response after a single intravenous (IV) dose of ustekinumab and entered a 5-year follow-up period.
The expanded FDA approval was based on results from two 8-week placebo-controlled induction trials and a 52-week maintenance study.
The latest Consensus Guidelines for the Management of PONV (CGM-PONV) recommend an assessment of a patient's baseline risk for PONV using a validated risk score based on independent predictors.
The guidelines were developed by the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America.
"IMBEDs enable new opportunities for gastrointestinal biomarker discovery and could transform the management and diagnosis of gastrointestinal disease," the authors write.
According to the review, a substantial number of patients can effectively decrease or completely discontinue use of PPIs, as often these agents are prescribed without an appropriate reason.
A Phase 3 clinical trial of patients with travelers' diarrhea demonstrated that Aemcolo was superior to placebo (P=.0008) and non-inferior to ciprofloxacin.
Recalled products include Teething Drops, Nausea Drops, Intestinal Colic Drops, Stomach Calm, Expectorant Cough Syrup, Silver-Zinc Throat Spray, and Argentum Elixir.
The intravenous formulation combines fosnetupitant (prodrug of netupitant), a substance P/NK1 receptor antagonist, and palonosetron, a 5-HT3 receptor antagonist.
The approval of Plenvu was based on multiple clinical trials including the NOCT study which compared Plenvu to the trisulfate bowel cleansing solution Suprep (sodium sulfate, potassium sulfate, magnesium sulfate oral solution; Braintree Laboratories) using a 2-day evening/morning split-dosing regimen.
The authors examined data from 8887 individuals who began TNF antagonist treatment for an autoimmune disease from 2001 through 2010 and were followed through 2012; 52% of these patients were screened for HBV before treatment.
The Reza Band is worn around the neck while sleeping and applies slight external pressure to the cricoid cartilage area, which increases the internal pressure of the upper esophageal sphincter (UES).
Previous research has suggested a genetic and functional link between IBD and PD, however evidence regarding this association has been limited.
"The combination of ethnicity/race with markers of insulin resistance and genetic factors might help identify obese youth at risk for developing fatty liver," the authors write.
To examine the occurrence of adverse reactions in this patient population, researchers from John Hopkins University, Baltimore, Maryland, conducted a retrospective analysis of IBD patients who received IV iron infusions between 2010 and 2014 in the commercial claims database, MarketScan.
Akynzeo IV combines fosnetupitant (prodrug of netupitant), a substance P/NK1 receptor antagonist, and palonosetron, a 5-HT3 receptor antagonist.
The randomized, double-blind, controlled trial (N=24,081) included patients with rheumatoid arthritis or osteoarthritis who required chronic NSAID treatment.
U.S. transplants using organs from overdose-death donors (ODDs) has increased 24-fold from 2000 to 2016, and transplant outcomes from organs donated by ODDs have been noninferior to those donated by trauma-death donors (TDDs) and medical-death donors (MDDs).
Factors associated with C. difficile infection incidence in the 30-day postoperative period after controlling for other variables include stoma reversal (odds ratio, 2.701; P<.001), smoking (odds ratio, 1.520; P<.022), steroids (odds ratio, 1.677; P<.048), and disseminated cancer.
Results showed that 46% (n=6) of substudy patients improved their histological fibrosis stage, while 38% maintained (n=5), and 15% experienced 1 stage progression (n=2).